Ghent University Academic Bibliography

Advanced

Fulvestrant (Faslodex (TM)) in advanced breast cancer: clinical experience from a Belgian cooperative study

P NEVEN, R PARIDAENS, G PELGRIMS, M MARTENS, A BOLS, J GOEMINNE, A VINDEVOGHEL, J DEMOL, B STRAGIER and J DE GREVE, et al. (2008) BREAST CANCER RESEARCH AND TREATMENT. 109(1). p.59-65
abstract
Fulvestrant (Faslodex (TM)) is a new estrogen receptor (ER) antagonist with no agonist effects that is licensed for the treatment of postmenopausal women with hormone-sensitive advanced breast cancer (ABC) who have progressed/recurred on prior antiestrogen therapy. The Faslodex (TM) Compassionate Use Program (CUP) provides expanded access to fulvestrant in countries where it is not yet available for patients who are not eligible to enter clinical trials. This analysis pools data from 402 patients who received fulvestrant as part of the CUP in Belgium, predominantly as 3rd- to 5th-line endocrine therapy for ABC. Two patients experienced partial responses and 118 experienced stable disease lasting >= 6 months, resulting in an overall clinical benefit rate of 29.9%. Fulvestrant was active in patients with multiple sites of metastases, visceral metastases, human epidermal growth factor receptor 2-positive disease and after heavy endocrine pre-treatment. Fulvestrant was well tolerated, with only six patients (1.5%) discontinuing treatment following adverse events. These data support the findings of previous CUP analyses and Phase II and III trials, suggesting that fulvestrant is a valuable addition to the treatment sequence for postmenopausal women with ABC who have progressed/recurred on prior endocrine therapy.
Please use this url to cite or link to this publication:
author
organization
year
type
journalArticle (original)
publication status
published
subject
keyword
compassionate use, advanced or metastatic breast cancer, endocrine, fulvestrant, postmenopausal, AROMATASE INHIBITOR THERAPY, PHASE-II TRIAL, POSTMENOPAUSAL WOMEN, RANDOMIZED-TRIAL, ENDOCRINE THERAPY, COMPASSIONATE USE, DOUBLE-BLIND, ANASTROZOLE, EXEMESTANE, TAMOXIFEN
journal title
BREAST CANCER RESEARCH AND TREATMENT
Breast Cancer Res. Treat.
volume
109
issue
1
pages
59-65 pages
Web of Science type
Article
Web of Science id
000255031000007
JCR category
ONCOLOGY
JCR impact factor
5.684 (2008)
JCR rank
17/141 (2008)
JCR quartile
1 (2008)
ISSN
0167-6806
DOI
10.1007/s10549-007-9628-2
language
English
UGent publication?
yes
classification
A1
id
397439
handle
http://hdl.handle.net/1854/LU-397439
date created
2008-04-21 14:56:00
date last changed
2009-03-10 14:39:37
@article{397439,
  abstract     = {Fulvestrant (Faslodex (TM)) is a new estrogen receptor (ER) antagonist with no agonist effects that is licensed for the treatment of postmenopausal women with hormone-sensitive advanced breast cancer (ABC) who have progressed/recurred on prior antiestrogen therapy. The Faslodex (TM) Compassionate Use Program (CUP) provides expanded access to fulvestrant in countries where it is not yet available for patients who are not eligible to enter clinical trials. This analysis pools data from 402 patients who received fulvestrant as part of the CUP in Belgium, predominantly as 3rd- to 5th-line endocrine therapy for ABC. Two patients experienced partial responses and 118 experienced stable disease lasting {\textrangle}= 6 months, resulting in an overall clinical benefit rate of 29.9\%. Fulvestrant was active in patients with multiple sites of metastases, visceral metastases, human epidermal growth factor receptor 2-positive disease and after heavy endocrine pre-treatment. Fulvestrant was well tolerated, with only six patients (1.5\%) discontinuing treatment following adverse events. These data support the findings of previous CUP analyses and Phase II and III trials, suggesting that fulvestrant is a valuable addition to the treatment sequence for postmenopausal women with ABC who have progressed/recurred on prior endocrine therapy.},
  author       = {NEVEN, P and PARIDAENS, R and PELGRIMS, G and MARTENS, M and BOLS, A and GOEMINNE, J and VINDEVOGHEL, A and DEMOL, J and STRAGIER, B and DE GREVE, J and FONTAINE, C and VAN DEN WEYNGAERT, D and BECQUART, D and BORMS, M and Cocquyt, Veronique and Van den Broecke, Rudy and SELLESLAGS, J and AWADA, A and DIRIX, L and VAN DAM, P and AZERAD, M and VANDENHOVEN, G and CHRISTIAENS, M and VERGOTE, I},
  issn         = {0167-6806},
  journal      = {BREAST CANCER RESEARCH AND TREATMENT},
  keyword      = {compassionate use,advanced or metastatic breast cancer,endocrine,fulvestrant,postmenopausal,AROMATASE INHIBITOR THERAPY,PHASE-II TRIAL,POSTMENOPAUSAL WOMEN,RANDOMIZED-TRIAL,ENDOCRINE THERAPY,COMPASSIONATE USE,DOUBLE-BLIND,ANASTROZOLE,EXEMESTANE,TAMOXIFEN},
  language     = {eng},
  number       = {1},
  pages        = {59--65},
  title        = {Fulvestrant (Faslodex (TM)) in advanced breast cancer: clinical experience from a Belgian cooperative study},
  url          = {http://dx.doi.org/10.1007/s10549-007-9628-2},
  volume       = {109},
  year         = {2008},
}

Chicago
NEVEN, P, R PARIDAENS, G PELGRIMS, M MARTENS, A BOLS, J GOEMINNE, A VINDEVOGHEL, et al. 2008. “Fulvestrant (Faslodex (TM)) in Advanced Breast Cancer: Clinical Experience from a Belgian Cooperative Study.” Breast Cancer Research and Treatment 109 (1): 59–65.
APA
NEVEN, P., PARIDAENS, R., PELGRIMS, G., MARTENS, M., BOLS, A., GOEMINNE, J., VINDEVOGHEL, A., et al. (2008). Fulvestrant (Faslodex (TM)) in advanced breast cancer: clinical experience from a Belgian cooperative study. BREAST CANCER RESEARCH AND TREATMENT, 109(1), 59–65.
Vancouver
1.
NEVEN P, PARIDAENS R, PELGRIMS G, MARTENS M, BOLS A, GOEMINNE J, et al. Fulvestrant (Faslodex (TM)) in advanced breast cancer: clinical experience from a Belgian cooperative study. BREAST CANCER RESEARCH AND TREATMENT. 2008;109(1):59–65.
MLA
NEVEN, P, R PARIDAENS, G PELGRIMS, et al. “Fulvestrant (Faslodex (TM)) in Advanced Breast Cancer: Clinical Experience from a Belgian Cooperative Study.” BREAST CANCER RESEARCH AND TREATMENT 109.1 (2008): 59–65. Print.